Investigation the effectiveness of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome

Document Type : Original Article

Authors

1 Department of Psychiatry, Iran University of Medical Sciences, Rasoul- E-Akram Hospital, Tehran, Iran

2 Department of Internal Medicine, School of Medicine Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Selective norepinephrine-serotonin receptor inhibitors (SNRIs) such as duloxetine have already shown beneficial effects on symptoms in irritable bowel syndrome (IBS) patients. The purpose of the present investigation was to assess the efficacy of duloxetine in the symptom and quality of life improvement in diarrhea predominant-IBS (IBS-D) patients. Materials and Methods: IN a randomized, double-blind and placebo-controlled study, sixty patients diagnosed with IBS-D (ROM-IV criteria), referred to the gastrointestinal clinic of Rasoul-e-Akram Hospital of Iran university of medical sciences, randomly assigned in the treatment groups, group A: patients who received 135 mg mebeverine tablet twice a day combined with 30 mg duloxetine capsule per day and group B, who received the same regimen, except for placebo capsule once per day instead of duloxetine for twelve weeks. The assessment was performed using the IBS severity index, and IBS quality of life questionnaire (IBS-QOF) at baseline, and weeks 4, 8, and 12 after beginning the treatment. Drug adverse effects and compliance to treatment were evaluated every 2 weeks after starting the treatment. Results: Sixty patients completed the trial. The duloxetine group showed significantly greater improvement on the IBS symptoms (P < 0.001), and the IBS-QOF (P < 0.001) in comparison to the placebo group at the endpoint. Conclusions: This study showed that adding duloxetine to mebeverine is safe with good efficacy on symptoms and QOL improvement in IBS-D patients. Besides, this study showed that 12 weeks' treatment duration is significantly more effective than 4 weeks' treatment, and drug adverse effects are more prominently seen in the first 2 weeks of treatment.

Keywords

1.
El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012;18:5151-63.  Back to cited text no. 1
    
2.
Jahangiri P, Jazi MS, Keshteli AH, Sadeghpour S, Amini E, Adibi P. Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1. Int J Prev Med 2012;3:S1-9.  Back to cited text no. 2
    
3.
Frolkis AD, Vallerand IA, Shaheen AA, Lowerison MW, Swain MG, Barnabe C, et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut 2019;68:1606-12.  Back to cited text no. 3
    
4.
Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg 2012;25:46-52.  Back to cited text no. 4
    
5.
Gendi R, Jahan N. Pharmacological and Non-pharmacological Treatments of Irritable Bowel Syndrome and Their Impact on the Quality of Life: A Literature Review. Cureus 2020;12:e9324.  Back to cited text no. 5
    
6.
Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterology. 2020;Epub ahead of print: [20 October 2020]. doi: 10.1136/flgastro-2019-101298  Back to cited text no. 6
    
7.
Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol 2017;10:253-75.  Back to cited text no. 7
    
8.
Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L, et al. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res 2015;29:1822-7.  Back to cited text no. 8
    
9.
Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. Clin Psychol Rev 2017;51:142-52.  Back to cited text no. 9
    
10.
Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther 2010;32:1221-33.  Back to cited text no. 10
    
11.
Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013;20:14-21.  Back to cited text no. 11
    
12.
Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol 2019;4:632-42.  Back to cited text no. 12
    
13.
Vahora IS, Tsouklidis N, Kumar R, Soni R, Khan S. How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome. Cureus 2020;12:e9871.  Back to cited text no. 13
    
14.
Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG Jr, Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009;24:423-8.  Back to cited text no. 14
    
15.
Forootan H, Taheri A, Hooshangi H, Mohammadi HR. Effects of fluoxetine, nortriptyline, and amitriptyline in IBS patients. Feyz Kashan Univ Med Sci Health Serv 2002;6:49-55.  Back to cited text no. 15
    
16.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.  Back to cited text no. 16
    
17.
Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-11.  Back to cited text no. 17
    
18.
Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987;32:257-66.  Back to cited text no. 18
    
19.
Masaeli N, Kheirabadi GR, Afshar H, Daghaghzadeh H, Maracy MR, Assadolahi F, et al. Validity, reliability, and factor analysis of Persian version of quality of life questionnaire for irritable bowel syndrome (IBS-QOL-34). J Res Med Sci 2013;18:492-6.  Back to cited text no. 19
    
20.
Kaviani H, Seyfourian H , Sharifi V, Ebrahimkhani N. Reliability and validity of Anxiety and Depression Hospital Scales (HADS): Iranian patients with anxiety and depression disorders. Tehran University Medical Journal 2009;67: 379-85.  Back to cited text no. 20
    
21.
Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:21-39.  Back to cited text no. 21
    
22.
Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:678-84.  Back to cited text no. 22
    
23.
Kaplan A, Franzen MD, Nickell PV, Ransom D, Lebovitz PJ. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract 2014;18:11-5.  Back to cited text no. 23
    
24.
Lewis-Fernández R, Lam P, Lucak S, Galfalvy H, Jackson E, Fried J, et al. An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder. J Clin Psychopharmacol 2016;36:710-5.  Back to cited text no. 24
    
25.
Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-41.  Back to cited text no. 25